Evidence map›Paper›PMID 33106816›Full record

ArticlemedRxiv : the preprint server for health sciences2020

A Sensitive, Rapid, and Portable CasRx-based Diagnostic Assay for SARS-CoV-2.

Daniel J Brogan, Duverney Chaverra-Rodriguez, Calvin P Lin, Andrea L Smidler, Ting Yang, Lenissa M Alcantara, Igor Antoshechkin, Junru Liu, Robyn R Raban, Pedro Belda-Ferre and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Daniel J BroganDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Duverney Chaverra-RodriguezDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Calvin P LinDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92092.
Andrea L SmidlerDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Ting YangDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Lenissa M AlcantaraDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Igor AntoshechkinDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Junru LiuDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Robyn R RabanDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Pedro Belda-FerreDepartment of Pediatrics, University of California San Diego, La Jolla, CA.
Rob KnightDepartment of Pediatrics, University of California San Diego, La Jolla, CA.
Elizabeth A KomivesDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92092.
Omar S AkbariDivision of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.

Funding

Mapping host-microbe-metabolite interactions in 3D to find diet-derived enhancers of immunityDP1AT010885 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KNIGHT, ROB · 2019 to 2023
$5.5M
Development of synthetic viral circuitry to regulate viruses in mosquito disease vectorsDP2AI152071 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AKBARI, OMAR SULTAN · 2019 to 2019
$2.4M
NCCIH NIH HHS DP1 AT010885NIAID NIH HHS DP2 AI152071
6 · The paper itself

Abstract

Since its first emergence from China in late 2019, the SARS-CoV-2 virus has spread globally despite unprecedented containment efforts, resulting in a catastrophic worldwide pandemic. Successful identification and isolation of infected individuals can drastically curtail virus spread and limit outbreaks. However, during the early stages of global transmission, point-of-care diagnostics were largely unavailable and continue to remain difficult to procure, greatly inhibiting public health efforts to mitigate spread. Furthermore, the most prevalent testing kits rely on reagent- and time-intensive protocols to detect viral RNA, preventing rapid and cost-effective diagnosis. Therefore the development of an extensive toolkit for point-of-care diagnostics that is expeditiously adaptable to new emerging pathogens is of critical public health importance. Recently, a number of novel CRISPR-based diagnostics have been developed to detect COVID-19. Herein, we outline the development of a CRISPR-based nucleic acid molecular diagnostic utilizing a Cas13d ribonuclease derived from

Identifiers

PMID33106816
PMCPMC7587836

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.